Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan;24(1):37-46.
doi: 10.1097/MNH.0000000000000088.

Cytochrome P450 eicosanoids in hypertension and renal disease

Fan Fan  1 , Yoshikazu Muroya, Richard J Roman
Affiliations
Free PMC article
Review

Cytochrome P450 eicosanoids in hypertension and renal disease

Fan Fan et al. Curr Opin Nephrol Hypertens. 2015 Jan.
Free PMC article

Abstract

Purpose of review: Cytochrome (CYP) P450 metabolites of arachidonic acid, 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) contribute to the regulation of renal tubular and vascular function. This review highlights the results of the recent genetic studies in humans and rodent models, indicating that these eicosanoids participate in the control of blood pressure (BP), chronic kidney disease (CKD), renal ischemia-reperfusion injury (IRI) and polycystic kidney disease (PKD).

Recent findings: Endogenous 20-HETE has been reported to play an essential role in the myogenic and tubuloglomerular feedback responses in the afferent arteriole, and a deficiency of 20-HETE contributes to the development of hypertension and renal injury in Dahl S rats. Mutations in CYP4A11 and CYP4F2 have been linked to elevated BP in humans. EETs have been shown to regulate epithelial sodium channel in the collecting duct, lower BP and have renoprotective properties. 20-HETE also opposes the development of CKD and IRI, and may play a role in PKD.

Summary: These studies indicate that CYP P450 metabolites of arachidonic acid play an important role in the control of BP, CKD, AKI and PKD. Drugs targeting these pathways could be useful in the treatment of IRI and CKD.

PubMed Disclaimer

Figures

Box 1
Box 1
no caption available
See this image and copyright information in PMC

References

    1. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82:131–185. - PubMed
    1. Fava C, Ricci M, Melander O, et al. Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: a sex-specific relation? Prostaglandins Other Lipid Mediat 2012; 98:75–85. - PubMed
    1. Ward NC, Tsai IJ, Barden A, et al. The effect of a single nucleotide polymorphism of the CYP4F2 gene on blood pressure and 20-hydroxyeicosatetraenoic acid excretion after weight loss. J Hypertens 2014; 32:1495–1502discussion 1502. - PubMed

    2. Paper showing that CYP4F2 genotype affects blood pressure response to weight loss.

    1. Liang JQ, Yan MR, Yang L, et al. Association of a CYP4A11 polymorphism and hypertension in the Mongolian and Han populations of China. Genet Mol Res 2014; 13:508–517. - PubMed

    2. Recent paper showing that CYP4A11 polymorphism is associated with hypertension in a Mongolian population.

    1. Sun D, Cuevas AJ, Gotlinger K, et al. Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure. Am J Physiol Heart Circ Physiol 2014; 306:H1146–H1153. - PMC - PubMed

    2. Evidence that knockout of soluble epoxide hydrolase decreases vascular tone and blood pressure in mice.

Publication types

MeSH terms